Cambridge Antibody Tech Group PLC
20 January 2006
20 January 2006, Regulatory Announcement: Annual Information Update
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
("the Company")
ANNUAL INFORMATION UPDATE FOR THE LAST 12 MONTHS UP TO AND INCLUDING 31 DECEMBER
2005
The Company announces that in accordance with the requirements of Prospectus
Rule 5.2, the following information has been published or made available to the
public during the twelve months ended 31 December 2005 in compliance with laws
and rules dealing with the regulation of securities, issuers of securities and
securities markets.
For the purpose of this update the information is only referred to and full
copies of each item can be found at the locations specified below.
1. Announcements made via a Regulatory Information Service.
All documents listed below were published via Regulatory News Service (RNS) on
the dates indicated.
Date of
Publication Title
RNS Announcement 20-Jan-05 Holding(s) in Company
RNS Announcement 25-Jan-05 Statement re Legal Action
RNS Announcement 27-Jan-05 Admission to trading
RNS Announcement 28-Jan-05 Statement re Court Ruling
RNS Announcement 3-Feb-05 Director Shareholding
RNS Announcement 3-Feb-05 Holding(s) in Company
RNS Announcement 4-Feb-05 Result of AGM
RNS Announcement 7-Feb-05 1st Quarter Results
RNS Announcement 10-Feb-05 Director Shareholding
RNS Announcement 14-Feb-05 CAT Legal action with Abbott
RNS Announcement 15-Feb-05 Holding(s) in Company
RNS Announcement 7-Mar-05 Director Shareholding
RNS Announcement 16-Mar-05 Director Shareholding
RNS Announcement 21-Mar-05 Abbott Permission to Appeal
RNS Announcement 22-Mar-05 Trabio Preliminary Results
RNS Announcement 31-Mar-05 Company Secretary Change
RNS Announcement 31-Mar-05 Blocklisting Interim Review
RNS Announcement 12-Apr-05 Holding(s) in Company
RNS Announcement 20-Apr-05 Notice of Results
RNS Announcement 16-May-05 Interim Results
RNS Announcement 20-May-05 Director Shareholding
RNS Announcement 20-May-05 Update Re Abbott
RNS Announcement 1-Jun-05 Holding(s) in Company
RNS Announcement 23-Jun-05 Clinical Update
RNS Announcement 18-Aug-05 Holding(s) in Company
RNS Announcement 19-Aug-05 Holding(s) in Company
RNS Announcement 12-Sep-05 3rd Quarter Results
RNS Announcement 12-Sep-05 Directorate Change
RNS Announcement 15-Sep-05 Director/PDMR Shareholding
RNS Announcement 23-Sep-05 Holding(s) in Company
RNS Announcement 30-Sep-05 Blocklisting Interim Review
RNS Announcement 5-Oct-05 Research Update
RNS Announcement 12-Oct-05 Holding(s) in Company
RNS Announcement 26-Oct-05 CAT & Abbott Agree Royalties
RNS Announcement 1-Nov-05 CAT Acquires Oncology Products
RNS Announcement 4-Nov-05 Admission to trading on LSE
RNS Announcement 25-Nov-05 Director/PDMR Shareholding
RNS Announcement 28-Nov-05 Final Results
RNS Announcement 28-Nov-05 Director/PDMR Shareholding
RNS Announcement 1-Dec-05 Director/PDMR Shareholding
RNS Announcement 5-Dec-05 Director/PDMR Shareholding
RNS Announcement 20-Dec-05 Holding(s) in Company
RNS Announcement 20-Dec-05 Director/PDMR Shareholding
RNS Announcement 23-Dec-05 Annual Report and Accounts
RNS Announcement 30-Dec-05 Director/PDMR Shareholding
RNS Announcement 4-Jan-06 Admission to trading on LSE
Copies of the documents published via RNS may be obtained from the Regulatory
News Service provided by the London Stock Exchange
( www.londonstockexchange.com/en-gb/pricesnews/marketnews/ ) and any related
documents are available at the UKLAs Document Viewing Facility, Financial
Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.
2. Documents filed at Companies House
The Company has submitted filings to Companies House in relation to the
appointment and resignation of directors, the resignation and appointment of the
Company Secretary, the allotment of shares and ordinary and special resolutions
passed at the Companys Annual General Meeting on 2 February 2005.
Electronic copies of these documents can be found on the Companies House website
at www.companies-house.gov.uk
Alternatively hard copies can be obtained from Companies House, Crown Way,
Cardiff, CF14 3UZ.
3. Documents filed with the Securities and Exchange Commission
The Company has submitted filings to the Securities and Exchange Commission by
virtue of having American Depositary Shares listed on the NASDAQ Stock Exchange.
Full details can be viewed at http://www.sec.gov/edgar/searchedgar/
companysearch.html
From this page enter the Companys mnemonic (CATG).
The Companys Annual Report for the year ended 30 September 2005 (published on 23
December 2005) can be found on the Companys website, as can the Interim Report
and Quarterly Reports for 2005 published on 7 February 2005 and 9 September 2005
and the 2006 AGM documents. The Companys website is www.cambridgeantibody.com
Copies of all documents referred to above are also available for inspection at
the Companys registered office, Milstein Building, Granta Park, Cambridge CB1
6GH, UK during normal business hours or by request from the Company Secretary.
In accordance with Article 27(3) of the Prospectus Directive Regulation, it is
acknowledged the whilst the information referred to above was up to date at the
time of publication, such disclosures may, at any time, become out of date due
to changing circumstances.
Further information regarding the Company and its activities is available at
www.cambridgeantibody.com
Justin Hoskins
Company Secretary
Cambridge Antibody Technology Group plc
Tel: +44 (0) 1223 471 471
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.